Discovery of IWP-051, a Novel Orally Bioavailable sGC Stimulator with Once-Daily Dosing Potential in Humans

Takashi Nakai,* Nicholas R. Perl, Timothy C. Barden, Andrew Carvalho, Angelika Fretzen, Peter Germano, G-Yoon J. Im, Hong Jin, Charles Kim, Thomas W.-H. Lee, Kimberly Long, Joel Moore, Jason M. Rohde, Renee Sarno, Chrissie Segal, Erik O. Solberg, Jenny Tobin, Daniel P. Zimmer, and Mark G. Currie

Ironwood Pharmaceuticals, Inc. 301 Binney Street Cambridge, Massachusetts 02142 United States

S Supporting Information

ABSTRACT: In recent years, soluble guanylate cyclase (sGC, EC 4.6.1.2) has emerged as an attractive therapeutic target for treating cardiovascular diseases and diseases associated with fibrosis and end-organ failure. Herein, we describe our design and synthesis of a series of 4-hydroxypyrimidine sGC stimulators starting with an internally discovered lead. Our efforts have led to the discovery of IWP-051, a molecule that achieves good alignment of potency, stability, selectivity, and pharmacodynamic effects while maintaining favorable pharmacokinetic properties with once-daily dosing potential in humans.

KEYWORDS: Soluble guanylate cyclase, sGC, NO-independent stimulators, heme-dependent sGC stimulators, nitric oxide, IWP-051

IWP-051

EC ₅₀	= 290 nM
Rat CL	= 0.6 mL/min/kg
Rat T _{1/2, iv}	= 4.1 h
Rat F _{po}	= 96 %
Rat PPB	= 99.9% bound

Soluble guanylate cyclase (sGC, EC 4.6.1.2) is a signal-transduction enzyme that binds nitric oxide (NO) and catalyzes the conversion of guanosine-5'-triphosphate (GTP) to the secondary messenger cyclic guanosine-3',5'-monophosphate (cGMP). The NO-sGC-cGMP signal-transduction pathway is involved in the regulation of various physiological processes, including smooth muscle relaxation, platelet inhibition, and vasodilation.¹ The NO-sGC-cGMP pathway plays an important role in coordinating blood flow to tissues, providing oxygen and nutrients, and removing waste products in response to local demands.² Impairment of sGC and/or reduced NO bioavailability has been implicated in the pathogenesis of cardiovascular, pulmonary, renal, and hepatic diseases.³ The therapeutic benefit of NO-donors such as organic nitrates is limited by lack of efficacy due to variable biometabolism⁴ and the development of NO tolerance.⁵

An alternative to NO-donors are sGC stimulators, a class of ligands that bind allosterically to the Fe(II) form of the heme-containing enzyme and stimulate the formation of cGMP.^{6,7} sGC stimulators can act both independently and in synergy with NO. In preclinical models, sGC stimulators have demonstrated anti-inflammatory and antifibrotic effects, as well as end-organ protections.^{8–11} The first marketed sGC stimulator, Bayer's riociguat (Adempas) (Figure 1), was approved in 2013 by the FDA for the treatment of pulmonary arterial hypertension (PAH) and inoperable chronic thromboembolic pulmonary hypertension (CTEPH) based on its ability to improve exercise capacity and symptomatic profile with disease severity defined by the World Health Organization functional classification system.¹² We sought to design an sGC stimulator with a sustained pharmacokinetic and pharmacody-

Figure 1. Three examples of sGC stimulators.

namic profile allowing once-daily dosing and potential to minimize the risk of hypotensive side effects.

Some known sGC stimulators, such as riociguat and BAY 41-2272,¹³ feature a fused ring structure (Figure 1). We have focused our discovery effort on sGC stimulators that utilize a novel, biaryl pyrazole structure, as exemplified by 1¹⁴ (Figure 1). 1 is a potent sGC stimulator as determined by production of cGMP in a human embryonic kidney (HEK) cellular assay in the presence of the NO-donor diethylenetriamine NONOate (DETA-NO, 10 μM) (EC₅₀ = 240 nM). When dosed at 1 and 10 mg/kg iv and po, respectively, 1 has a 26 min iv half-life and is orally bioavailable (F_{po} = 53%) in rat. An off-target screen revealed that 1 binds to the κ-opioid (KOP) receptor (IC₅₀ =

Received: December 11, 2015

Accepted: February 24, 2016

Published: February 24, 2016

1.2 μM) and is a functional agonist ($\text{EC}_{50} = 1.5 \mu\text{M}$). This off-target activity, coupled with a short half-life in rat, precluded the advancement of **1** into additional preclinical models. We therefore focused on designing sGC stimulators with cellular potency comparable to or better than that of **1** with reduced KOP binding and a better pharmacokinetic profile.

With the goal of improving the selectivity and the pharmacokinetic profile of **1**, we sought to introduce functionality at the pyrimidine 5-position. In the course of this effort, amidine **2a** was treated with cyanoacrylate **3a** (Scheme 1). In contrast to a previous report detailing a similar

Scheme 1. Synthesis of Analogs **4** and **5**

reaction,¹⁵ the desired 4-amino product **4** was obtained in low yield (4%) with the hydroxypyrimidine **5** predominating as a major product (38%). While **5** has attenuated cellular potency ($\text{EC}_{50} = 500 \text{ nM}$) relative to **1**, the compound is more stable in male rat liver microsomes (RLM, $\text{CL}_{\text{int}} = 14$ versus $26 \mu\text{L}/\text{min}/\text{mg}$ protein) and comparably stable in human liver microsomes (HLM, $\text{CL}_{\text{int}} = 8$ versus $10 \mu\text{L}/\text{min}/\text{mg}$ protein). When **5** was dosed orally in rats, it exhibited a significantly higher maximum plasma concentration (C_{max}) and area under the curve (AUC) compared with our previously synthesized 4-amino pyrimidine compounds.¹⁶ On the basis of these encouraging data we focused our efforts on expanding the 4-hydroxypyrimidine series.

The general synthesis of pyrimidine analogs is depicted in Scheme 2.^{17–20} Starting with readily accessible methyl ketones

Scheme 2. General Synthesis of Pyrimidine Analogs

of general structure **6**, Claisen condensation with diethyl oxalate in the presence of lithium hexamethyldisilazide (LHMDS) at low temperature, followed by acetic acid-mediated cyclization with benzyl and alkyl hydrazines gave intermediate pyrazole esters **7**. Conversion of the pyrazole esters to amidines **2** was accomplished by treatment of the esters with excess trimethylaluminum and ammonium chloride at elevated temperatures.²¹ Condensation of amidines **2** with

acrylates **3** in the presence of base such as 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) or triethylamine delivered the desired pyrimidines, which could then undergo further transformations to access additional pyrazole analogs.²²

Using the isoxazole-substituted pyrazole as a template, various pyrimidine analogs were profiled (Table 1). The

Table 1. Pyrimidine Ring SAR

Compound	R ₁	R ₂	R ₃	EC ₅₀ (nM) ^a	CL _{int} RLM, HLM (μL/min/mg protein)
1	NH ₂	H	H	240	26, 10
5	OH	CN	H	500	14, 8
8	OH	H	H	ND (92) ^b	15, 12
9	OH	-NHBz	H	ND (53)	26, 14
10	OH	-CMe ₂ OH	H	ND (40)	8, 8
11	OH	F	H	290	6, 3
12	NH ₂	F	H	190	17, 14
13	OH	Cl	H	590	5, 7
14	OH	CF ₃	H	ND (54)	20, 19
15	OH	-SO ₂ Me	H	900	13, 15
16	OH	-SO ₂ Ph	H	350	27, 18
17	OH	-SO ₂ (<i>p</i> -Cl-Ph)	H	160	15, 6
18	OH	-SO ₂ N(Me) ₂	H	ND (87)	24, 8
19	OH	-SO ₂ N(Me)(Ph)	H	730	58, 179
20	OH	F	Me	ND (70)	16, 9
21	OMe	F	H	320	95, 20

Potency measured in human embryonic kidney (HEK) cells in the presence of $10 \mu\text{M}$ DETA-NO. ^aThe geometric mean of at least two repeated runs. ^bNot determined due to incomplete concentration response. Maximal efficacy (%E_{max}) at $30 \mu\text{M}$ shown in parentheses.

electronic nature of the substituent at the pyrimidine 5-position has a significant influence on sGC potency. A reduction in cellular potency is observed when the electron-withdrawing nitrile of **5** ($\text{EC}_{50} = 500 \text{ nM}$) is replaced with a proton (**8**, $\text{EC}_{50} = \text{ND}$), an electron-donating benzoyl-protected amino group (**9**, $\text{EC}_{50} = \text{ND}$), or a carbinol (**10**, $\text{EC}_{50} = \text{ND}$). Alternatively, replacement of the nitrile with other electron-withdrawing groups generally results in similarly potent compounds. For instance, 5-fluoro analog **11** ($\text{EC}_{50} = 290 \text{ nM}$) is more potent than **5** and is also stable in the presence of RLM ($\text{CL}_{\text{int}} = 6 \mu\text{L}/\text{min}/\text{mg}$ protein) and HLM ($\text{CL}_{\text{int}} = 3 \mu\text{L}/\text{min}/\text{mg}$ protein). Not all compounds featuring electron withdrawing groups at the 5-position are potent stimulators. While chloro-substituted derivative **13** ($\text{EC}_{50} = 590 \text{ nM}$) performs comparably to the nitrile analog **5**, the increased electron withdrawing nature of the trifluoromethyl group is detrimental to cellular sGC potency (**14**, $\text{EC}_{50} = \text{ND}$).

A number of 5-substituted sulfones and sulfonamides possess moderate-to-good cellular potency. While methyl sulfone **15** is moderately potent ($\text{EC}_{50} = 900 \text{ nM}$), replacing the methyl group with a phenyl moiety increases the potency (**16**, $\text{EC}_{50} =$

350 nM). Additionally, the 4-chlorophenyl sulfone **17** is the most potent compound in the series (EC_{50} = 160 nM). Sulfonamides are less potent than their sulfone counterparts (**18**, EC_{50} = ND and **19**, EC_{50} = 730 nM) and **19** is also metabolically unstable in vitro (RLM CL_{int} = 58 μ L/min/mg protein, HLM CL_{int} = 179 μ L/min/mg protein). Introduction of the methyl group to the pyrimidine 6-position of **11** attenuates cellular potency (**20**, EC_{50} = ND). While O-methylation of **11** has no effect on potency (**21**, EC_{50} = 320 nM), the metabolic stability is decreased presumably due to oxidative O-demethylation. Finally, the addition of a fluorine atom at the pyrimidine 5-position imparts a greater improvement in potency for hydroxypyrimidine **8** (**8**, EC_{50} = ND vs **11**, EC_{50} = 290 nM) compared to aminopyrimidine **1** (**1**, EC_{50} = 240 nM vs **12**, EC_{50} = 190 nM).

Holding the 5-fluoro-4-hydroxypyrimidine moiety constant, we next explored modifications to the pyrazole 5-position (Table 2). Adjustments to the isoxazole moiety significantly

Table 2. SAR of the R4 Group

Compound	R ₄	EC_{50} (nM) ^a	CL_{int} , RLM, HLM (μ L/min/mg protein)
11		290	6, 3
22		ND (68) ^b	4, 0
23		1500	68, 42
24		ND (78)	9, 4
25		ND (23)	249, 118
26		180	129, 169
27		ND (35)	39, 9
28		ND (73)	9, 7
29		ND (26)	10, 0

Potency measured in human embryonic kidney (HEK) cells in the presence of 10 μ M DETA-NO. ^aThe geometric mean of at least two repeated runs. ^bNot determined due to incomplete concentration response. Maximal efficacy (% E_{max}) at 30 μ M shown in parentheses.

affect potency in the cellular sGC assay. Introduction of nitrogen into the isoxazole framework of **11** to give 1,2,4-oxadiazole **22** (EC_{50} = ND) dramatically reduces sGC activity, although the metabolic stability is maintained. Oxazoles **23** (EC_{50} = 1500 nM) and **24** (EC_{50} = ND) also suffer a reduction in potency. The limited space afforded in this vector is highlighted by 5-methylisoxazole **25**, in which the addition of a single methyl group to **11** drastically reduces the potency. When the isoxazole is replaced by a larger isothiazole (**26**, EC_{50} = 180 nM) cellular potency is retained, albeit at the expense of microsomal stability (RLM CL_{int} = 129 μ L/min/mg protein, HLM CL_{int} = 169 μ L/min/mg protein). Beyond 5-membered heteroarenes, 2-pyridine **27** (EC_{50} = ND), nitrile **28** (EC_{50} = ND) and cyclopropane **29** (EC_{50} = ND) all fail to reach full efficacy in this particular series.

With the 5-fluoro-4-hydroxypyrimidine and isoxazole moieties established at the pyrazole 3- and 5-positions, respectively, we next optimized the pyrazole nitrogen substitution (Table 3).

Table 3. SAR of the R5 Group

Compound	R ₅	EC_{50} (nM) ^a	CL_{int} , RLM, HLM (μ L/min/mg protein)
11		290	6, 3
30		880 (n=1)	10, 11
31		370	3, 7
32		380	2, 5
33		240 (n=1)	79, 8
34		280	13, 11
35		530	4, 4
36		ND (44) ^b	7, 15
37		ND (83)	32, 23
38		1500 (n=1)	4, 6

Potency measured in human embryonic kidney (HEK) cells in the presence of 10 μ M DETA-NO. ^aThe geometric mean of at least two repeated runs, unless stated otherwise. ^bNot determined due to incomplete concentration response. Maximal efficacy (% E_{max}) at 30 μ M shown in parentheses.

The 2-fluoro benzyl substituent confers sGC potency, as 2-H benzyl analog **30** (EC_{50} = 880 nM) is less potent than **11**. sGC activity is maintained with the introduction of a halogen atom (**31**, EC_{50} = 370 nM and **32**, EC_{50} = 380 nM) or a methyl group (**33**, EC_{50} = 240 nM) adjacent to the benzyl fluorine. However, the introduction of a methyl group introduces a metabolic site that results in decreased RLM stability (CL_{int} = 79 μ L/min/mg protein). While the sGC activity of the 3-fluorothiophene bioisostere **34** is maintained (EC_{50} = 280 nM), the thiophene is less stable (RLM CL_{int} = 13 μ L/min/mg protein, HLM CL_{int} = 11 μ L/min/mg protein) than the parent **11**.

As with the pyrazole 5-position, electronic manipulations to the 2-fluorobenzyl group can result in a significant loss of potency in this particular series. Introduction of a nitrogen atom (**36**, EC_{50} = ND) is not tolerated. Incorporation of perfluorinated alkyl groups²³ also adversely affects sGC activity (**37**, EC_{50} = ND and **38**, EC_{50} = 1500 nM) in the cellular assay. Based on the exploration of the pyrazole N-1 functionality, we determined that 2-fluorobenzyl substitution was optimal for this 5-fluoro-4-hydroxypyrimidine scaffold.

In purified recombinant human sGC enzyme assay (Enzo Life Sciences) and whole cell (HEK) assays, 11 (hereafter referred to as IWP-051) as well as other compounds of this class stimulate cGMP production in the absence of NO and demonstrate synergy with NO in a concentration responsive manner. In the absence of NO, IWP-051 is less potent and it shows a lower degree of sGC stimulation as measured by maximal efficacy (% $E_{\max}$). This profile is consistent with the stimulator class of sGC agonist compounds and provides evidence that IWP-051 is a direct sGC stimulator.²⁴

IWP-051 is highly protein bound in both rat (99.9% bound) and human (99.4% bound) plasma. Albumin, a major component of plasma, binds acidic compounds,²⁵ and IWP-051 is mildly acidic with a pK_a of 5.75. The acidic hydroxypyrimidine proton also appears to affect the aqueous solubility, as the thermodynamic solubility of IWP-051 increases with increasing pH (3 $\mu\text{g/mL}$ at pH = 7.4 and 142 $\mu\text{g/mL}$ at pH = 9.2). IWP-051 is readily absorbed in the gut with high permeability ($P_{\text{app, A-B}} = 21.8 \times 10^{-6} \text{ cm/s}$). Further, the compound does not inhibit cytochrome P450 (CYP) isozymes (<20% inhibition at 10 μM of CYP 3A4, 2D6, 2C9, 1A2, and 2C19). With regard to off-target activity, it has minimal activity in a screen of over 60 potential targets, including the KOP receptor (21% binding at 10 μM). For a representative panel of phosphodiesterases (PDE1B, PDE2A₁, PDE3A, PDE4D₂, PDE5, PDE10A₁) less than 30% inhibition was observed at 10 μM of IWP-051. The lack of inhibition of phosphodiesterases further supports the mechanism of the direct stimulation of sGC.

Pharmacokinetic data associated with IWP-051 in multiple species are represented in Table 4. IWP-051 has a low volume

Table 4. Pharmacokinetic Parameters of IWP-051 in Mouse, Rat, and Dog^a

parameter	mouse	rat	dog
CL (mL/min/kg)	5.0 $\pm$ 0.1	0.6 $\pm$ 0.1	0.2 $\pm$ 0.01
$t_{1/2 \text{ iv}}$ (h)	3.4 $\pm$ 0.5	4.1 $\pm$ 0.5	5.1 $\pm$ 0.9
V_{dss} (mL/kg)	1300 $\pm$ 100	180 $\pm$ 60	95 $\pm$ 12
T_{max} (h)	1.7 $\pm$ 1.0	5.3 $\pm$ 1.2	3.3 $\pm$ 1.2
C_{max} (ng/mL)	1000 $\pm$ 300	1500 $\pm$ 400	3500 $\pm$ 600
$\text{AUC}_{0-\infty}$ (min· $\mu\text{g/mL}$)	270 $\pm$ 75	1500 $\pm$ 280	2500 $\pm$ 290
F_{po} (%)	>100	96 $\pm$ 26	45 $\pm$ 3

^aOral doses of compound administered as solutions in PEG400 at 1 mg/kg; iv doses administered in 10% DMI, 35% propylene glycol, 15% EtOH, 40% DSW (5% dextrose in water) at 0.1 mg/kg. Please see the Supporting Information for additional detail.

of distribution ($V_{\text{dss}} = 180 \text{ mL/kg}$), low clearance ($\text{CL} = 0.6 \text{ mL/min/kg}$), and long half-life ($t_{1/2} = 4.1 \text{ h}$) in rat, all of which are consistent with high plasma protein binding and a small free fraction in plasma. When dosed orally at 1 mg/kg, IWP-051 is slowly absorbed and reaches a C_{max} of over 4 μM (free drug $C_{\text{max}} \sim 80 \text{ nM}$) at 5 h, with high bioavailability ($F_{\text{po}} = 96 \pm 26\%$). In dog and mouse, the profile of IWP-051 is similar to low clearance, moderate half-life, and high C_{max} .²⁶ Standard allometric scaling using mouse, rat and dog PK parameters predicts a human elimination half-life of about 8 h, consistent with once-daily dosing.²⁷ The slow absorption of IWP-051 may be related to its pH-dependent solubility profile with solubility-limited absorption in the upper GI.

When dosed orally as a PEG400 solution in normotensive Sprague–Dawley rats, IWP-051 elicits a dose dependent

lowering of mean arterial pressure (MAP), with a 10 mmHg drop in MAP at the minimum effective dose of 1 mg/kg (Figure 2).²⁸ The reduction in MAP approaches -30 mmHg at the 30 mg/kg dose. At the 10 mg/kg dose and above, the reduction in MAP is maintained through 24 h.

Figure 2. IWP-051 (1, 10, and 30 mg/kg in PEG400) and Bay 41-2272 (10 mg/kg in 0.5% methylcellulose, Sigma-Aldrich) were dosed orally to male, normotensive Sprague–Dawley rats. Vehicle-subtracted mean arterial pressure (Δ_{MAP}) in mmHg was monitored for 12–24 h via a conscious, tethered rat model. Data is represented as the change from their own vehicles as 1 h averages $\pm$ SEM, $n = 5-9$.

In summary, IWP-051 is a novel, potent, orally bioavailable sGC stimulator that was discovered through the structural manipulation of a 1,3,5-substituted pyrazole scaffold. IWP-051 exhibit minimal off-target liabilities, including CYP and phosphodiesterase activities. Across species, IWP-051 has high protein binding, low clearance, long half-life, and slow absorption. It also exhibits sustained and dose-dependent reduction in MAP in rats. Pharmacokinetic modeling suggests that IWP-051 may have once-daily dosing potential in humans. Based on its in vitro and in vivo profile, IWP-051 is a useful molecule for probing pharmacologic utility of sustained sGC stimulation in preclinical models of human disease.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acsmmedchemlett.5b00479.

Synthetic procedures, compound characterization data, description of the cGMP generation assay, determination of cGMP concentrations using LC-MS/MS, error propagation for potency, description of the rat liver microsomal and human liver microsomal stability assays, pharmacokinetic data of select compounds, and procedures for measuring hemodynamic parameters. (PDF)

■ AUTHOR INFORMATION

Corresponding Author

* E-mail: tnakai@ironwoodpharma.com.

Notes

The authors declare the following competing financial interest(s): All authors own stock/stock options in Ironwood Pharmaceuticals, Inc.

■ ACKNOWLEDGMENTS

We thank our colleagues at Ironwood Pharmaceuticals, especially, Dr. Vishnu Karnati and Dr. Song Xu, for providing starting materials and intermediates. We thank Dr. James

Shepeck II and Dr. Paul Renhowe for helpful discussions. We also thank Sam Rivers for his technical assistance.

■ ABBREVIATIONS

sGC, soluble guanylate cyclase; PAH, pulmonary arterial hypertension; CTEPH, chronic thromboembolic pulmonary hypertension; HEK, human embryonic kidney; DETA-NO, diethylenetriamine NONOate; KOP, κ -opioid; $C_{\max}$, maximum plasma concentration; AUC, area under the curve; EtOH, ethanol; LHMDs, lithium hexamethyldisilazide; DBU, 1,8-diazabicyclo[5.4.0]undec-7-ene; RLM, rat liver microsomes; HLM, human liver microsomes; CYP, cytochrome P450 isozymes; MAP, mean arterial pressure; SEM, the standard error of the mean

■ REFERENCES

- (1) Ignarro, L. J.; Buga, G. M.; Wood, K. S.; Byrns, R. E.; Chandhuri, G. Endothelium derived relaxing factor produced and released from artery and vein is nitric oxide. *Proc. Natl. Acad. Sci. U. S. A.* **1987**, *84*, 9265–9269.
- (2) Pohl, U.; de Wit, C. A unique role of NO in the control of blood flow. *News in Physiological Sciences* **1999**, *14*, 74–80.
- (3) Stasch, J.-P.; Hobbs, A. J. NO-independent, haem-dependent soluble guanylate cyclase stimulators. In *Handbook of Experimental Pharmacology*; Schmidt, H. H. H. W., Hofmann, F., Stasch, J.-P., Eds.; Springer: Berlin, 2009; Vol. 199, pp 277–308.
- (4) Li, Y.; Zhang, D.; Jin, W.; Shao, C.; Yan, P.; Xu, C.; Sheng, H.; Liu, Y.; Yu, J.; Xie, Y.; Zhao, Y.; Lu, D.; Nebert, D. W.; Harrison, D. C.; Huang, W.; Jin, L. Mitochondrial aldehyde dehydrogenase-2 (ALDH2) Glu504Lys polymorphism contributes to the variation in efficacy of sublingual nitroglycerin. *J. Clin. Invest.* **2006**, *116*, 506–511.
- (5) Münzel, T.; Daiber, A.; Mülsch, A. Explaining the phenomenon of nitrate tolerance. *Circ. Res.* **2005**, *97*, 618–628.
- (6) Evgenov, O. V.; Pacher, P.; Schmidt, P. M.; Haskö, G.; Schmidt, H. H. H. W.; Stasch, J.-P. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. *Nat. Rev. Drug Discovery* **2006**, *5*, 755–768.
- (7) Friebe, A.; Koesling, D. Mechanism of yc-1-induced activation of soluble guanylate cyclase. *Mol. Pharmacol.* **1998**, *53*, 123–127.
- (8) Ahluwalia, A.; Foster, P.; Scotland, R. S.; McLean, P. G.; Mathur, A.; Perretti, M.; Moncada, S.; Hobbs, A. J. Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment. *Proc. Natl. Acad. Sci. U. S. A.* **2004**, *101*, 1386–1391.
- (9) Beyer, C.; Reich, N.; Schindler, S. C.; Akhmetshina, A.; Dees, C.; Tomcik, M.; Hirth-Dietrich, C.; von Degenfeld, G.; Sandner, P.; Distler, O.; Schett, G.; Distler, J. H. W. Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis. *Ann. Rheum. Dis.* **2012**, *71*, 1019–1026.
- (10) Beyer, C.; Zenzmaier, C.; Palumbo-Zerr, K.; Mancuso, R.; Distler, A.; Dees, C.; Zerr, P.; Huang, J.; Maier, C.; Pachowsky, M. L.; Friebe, A.; Sandner, P.; Distler, O.; Schett, G.; Berger, P.; Distler, J. H. W. Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGF β signaling. *Ann. Rheum. Dis.* **2015**, *74*, 1408–1416.
- (11) Masuyama, H.; Tsuruda, T.; Sekita, Y.; Hatakeyama, K.; Imamura, T.; Kato, J.; Asada, Y.; Stasch, J.-P.; Kitamura, K. Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart. *Hypertens. Res.* **2009**, *32*, 597–603.
- (12) Conole, D.; Scott, L. J. Riociguat: first global approval. *Drugs* **2013**, *73*, 1967–75.
- (13) Mittendorf, J.; Weigand, S.; Alonso-Alija, C.; Bischoff, E.; Feurer, A.; Gerisch, M.; Kern, A.; Knorr, A.; Lang, D.; Muentner, K.; Radtke, M.; Schirok, H.; Schlemmer, K.-H.; Stahl, E.; Straub, A.; Wunder, F.; Stasch, J.-P. Discovery of riociguat (BAY 63–2521): A potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. *ChemMedChem* **2009**, *4*, 853–865.
- (14) Additional pharmacokinetic parameters of **1** are provided in the [Supporting Information](#).
- (15) Straub, A.; Benet-Buchholz, J.; Fröde, R.; Kern, A.; Kholsdorfer, C.; Schmitt, P.; Schwarz, T.; Siefert, H.-M.; Stasch, J.-P. Metabolites of orally active NO-independent pyrazolopyridine stimulators of soluble guanylate cyclase. *Bioorg. Med. Chem.* **2002**, *10*, 1711–1717.
- (16) Additional pharmacokinetic parameters of **5** are provided in the [Supporting Information](#). Also: Nakai, T.; Perl, N. R.; Im, G.-Y. J.; Lee, T. W.-H.; Rohde, J. M.; Kim, C.; Moore, J.; Barden, T. C.; Fretzen, A.; Butler, C.; Long, K.; Sarno, R.; Germano, P.; Jin, H.; Carvalho, A.; Solberg, E. O.; Zimmer, D. Discovery of a novel, orally bioavailable soluble guanylate cyclase stimulator (IWP-051). Presented at *12th Winter Conference on Medicinal & Bioorganic Chemistry*, Steamboat Springs, Colorado, January 24–29, 2015.
- (17) Kim, C.; Nakai, T.; Moore, J.; Perl, N. R.; Im, G.-Y. J.; Barden, T. C.; Iyengar, R. R.; Zimmer, D. P.; Fretzen, A.; Renhowe, P. A. 2-Benzyl,3-(pyrimidin-2-yl) substituted pyrazoles useful as sgc stimulators. WO 2013/101830A1.
- (18) Kim, C.; Nakai, T.; Lee, T. W.-H.; Moore, J.; Perl, N. R.; Rhode, J. SGC stimulators. WO 2012/064559 A1.
- (19) Im, G.-Y. J.; Iyengar, R.; Moore, J.; Fretzen, A. SGC stimulators. WO 2014/047111A1.
- (20) Nakai, T.; Moore, J.; Perl, N. R.; Iyengar, R. R.; Mermerian, A.; Im, G.-Y. J.; Lee, T. W.-H.; Hudson, C.; Rennie, G. R.; Jia, J.; Renhowe, P. A.; Barden, T. C.; Yu, X. Y.; Shepeck, J. E.; Iyer, K.; Jung, J. SGC stimulators. WO 2014/144100 A2.
- (21) Gielen, H.; Alonso-Alija, C.; Hendrix, M.; Niewöhner, U.; Schauss, D. A novel approach to amidines from esters. *Tetrahedron Lett.* **2002**, *43*, 419–421.
- (22) Detailed procedures for the synthesis of all analogs including **14** and **26** are described in the [Supporting Information](#).
- (23) Raghavan, S.; Stelmach, J. E.; Smith, C. J.; Li, H.; Whitehead, A.; Waddell, S. T.; Chen, Y.-H.; Miao, S.; Ornoski, O. A.; Garfunkle, J.; Liao, X.; Chang, J.; Han, X.; Guo, J.; Groeper, J. A.; Brockunier, L. L.; Rosauer, K.; Parmee, E. R. Soluble guanylate cyclase activators. WO 2011/149921A1.
- (24) Milne, T.; Butler, C.; Long, K.; Miyashiro, J.; Bernier, S.; Jacobson, S.; Tobin, J.; Solberg, E.; Shea, C.; Germano, P.; Moore, J.; Chien, Y.-t.; Zimmer, D. Iwp-051, a novel, orally available small molecule soluble guanylate cyclase (sgc) stimulator with once-daily dosing potential for the treatment of cardiovascular diseases. Presented at *8th International Nitric Oxide Conference & 6th International Nitrite/Nitrate Conference*, Cleveland, OH, June 16–20th, 2014.
- (25) Kerns, E. H.; Di, Li *Drug-like properties: concepts, structure design and methods: from ADME to toxicity optimization*; Elsevier: Oxford, 2008; pp 188.
- (26) Urine collected from dogs following the PO dose contained <5% of the circulating IWP-051 excreted as parent. The metabolites in urine were not quantified nor feces samples collected. Due to its low metabolic turnover and low observed in life clearance, IWP-051 is most likely cleared as parent through an undetermined route.
- (27) The interspecies scaling approach to predict clearance in humans from mouse, rat and dog data was performed using simple allometry as previously described: Mahmood, I.; Balian, J. D. Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. *Xenobiotica* **1996**, *26* (9), 887–95.
- (28) The method for measuring hemodynamic parameters is provided in the [Supporting Information](#).